Delivery Order SPE2DR25D3505-SPE2DR26F94A9
- Not listed
- The Defense Logistics Agency awarded a $14,609.25 delivery order to AmerisourceBergen Drug Corp on November 13, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by December 5, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $9,739.52 to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units). This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures and scheduled for completion by December 23, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,739.52 to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules (30-count packages) on November 7, 2025, with completion scheduled for December 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,609.25 to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules (30-count units) on December 8, 2025, with a completion deadline of December 30, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is a child contract issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units) with a ceiling value of $29,218.50. This firm fixed-price delivery order, with an ultimate completion date of December 23, 2025, represents a non-set-aside competitive award and will be performed at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order valued at $13,862.79 to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules (30-count) under a firm fixed price contract. The award, issued on September 26, 2025, with an ultimate completion date of October 20, 2025, represents a non-competitive, competitively awarded transaction. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this contract at its...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules (30-count) under a firm fixed-price contract with a ceiling value of $4,620.93. The award was made on September 15, 2025, with an ultimate completion date of October 6, 2025. This non-set-aside award represents a competitive procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Zeposia 0.92 mg capsules (30-count) with a ceiling value of $13,862.79. This firm fixed-price delivery order represents a non-competitive award and is scheduled for completion by August 29, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a leading pharmaceutical distributor, AmerisourceBergen maintains a...
- The Defense Logistics Agency awarded a $13,862.79 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units). This is a firm fixed-price contract with an ultimate completion date of August 20, 2025, and represents a non-competitive set-aside delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be performed and delivered from the company's Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $18,483.72 for Zeposia 0.92 mg capsules (30-count) on September 24, 2025, with completion scheduled for October 16, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a single transaction under the company's broader pharmaceutical supply...
- SPE2DR25D3505Indefinite Delivery Contract
- SPE2DR25D3505-SPE2DR26F94A9Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $14,609.25 to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules (30-count packaging) on November 26, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by December 18, 2025. The award is performed from the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products, vaccines, and medical supplies to support military healthcare programs and other government medical systems. Zeposia, an immunosuppressant medication used in the treatment of certain autoimmune conditions, represents the type of specialty pharmaceutical products procured through this strategic contract vehicle to support Defense Health Agency operations and other federal healthcare beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.6k | 11/25/25 |